BNP Paribas Financial Markets’s Takeda Pharmaceutical TAK Stock Holding History

BNP Paribas Financial Markets’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4M	Buy	714,143 +523,730	+275%	+$8.67M	﹤0.01%	1559
2026 Q1	$3.53M	Buy	190,413 +4,864	+3%	+$85.4K	﹤0.01%	2287
2025 Q4	$2.89M	Buy	185,549 +174,355	+1,558%	+$2.49M	﹤0.01%	2396
2025 Q3	$164K	Sell	11,194 -651	-5%	-$9.67K	﹤0.01%	4099
2025 Q2	$183K	Buy	11,845 +11,169	+1,652%	+$165K	﹤0.01%	3797
2025 Q1	$10.1K	Sell	676 -500,001	-100%	-$7.01M	﹤0.01%	4714
2024 Q4	$6.63M	Buy	500,677 +497,457	+15,449%	+$6.83M	﹤0.01%	1603
2024 Q3	$45.8K	Buy	3,220 +2,596	+416%	+$36.8K	﹤0.01%	3630
2024 Q2	$8.07K	Sell	624 -88	-12%	-$1.17K	﹤0.01%	3742
2024 Q1	$9.89K	Hold	712	–	–	﹤0.01%	3689
2023 Q4	$10.2K	Sell	712 -83	-10%	-$1.18K	﹤0.01%	3713
2023 Q3	$12.3K	Sell	795 -1,986	-71%	-$30.7K	﹤0.01%	3607
2023 Q2	$43.7K	Buy	2,781 +759	+38%	+$12.4K	﹤0.01%	3505
2023 Q1	$33.3K	Buy	2,022 +1,062	+111%	+$16.9K	﹤0.01%	3477
2022 Q4	$15K	Hold	960	–	–	﹤0.01%	3575
2022 Q3	$12.5K	Sell	960 -2,804	-74%	-$39K	﹤0.01%	4157
2022 Q2	$52.8K	Sell	3,764 -90,613	-96%	-$1.29M	﹤0.01%	3545
2022 Q1	$1.35M	Sell	94,377 -178,625	-65%	-$2.62M	﹤0.01%	2110
2021 Q4	$3.72M	Buy	273,002 +229,978	+535%	+$3.23M	0.01%	1552
2021 Q3	$705K	Buy	43,024 +888	+2%	+$14.9K	﹤0.01%	2580
2021 Q2	$709K	Sell	42,136 -215,754	-84%	-$3.67M	﹤0.01%	2367
2021 Q1	$4.71M	Sell	257,890 -75,000	-23%	-$1.35M	0.01%	1205
2020 Q4	$6.06M	Buy	332,890 +21,678	+7%	+$380K	0.01%	1029
2020 Q3	$5.55M	Sell	311,212 -30,183	-9%	-$550K	0.01%	1032
2020 Q2	$6.12M	Buy	341,395 +8,539	+3%	+$153K	0.01%	956
2020 Q1	$5.05M	Buy	332,856 +13,837	+4%	+$251K	0.01%	976
2019 Q4	$6.29M	Buy	319,019 +5,064	+2%	+$96.9K	0.01%	1080
2019 Q3	$5.4M	Sell	313,955 -6,730	-2%	-$116K	0.01%	1037
2019 Q2	$5.68M	Buy	+320,685	New	+$5.84M	0.01%	982

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

BNP Paribas Financial Markets's TAK Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Takeda Pharmaceutical (TAK) stake by 275% in Q2 2026, buying an estimated $8.67M and bringing the position to 714,143 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1559.

BNP Paribas Financial Markets first reported a position in TAK in Q2 2019 and has held it in 29 quarters since. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

BNP Paribas Financial Markets held 714,143 shares of Takeda Pharmaceutical worth $11.4M as of Q2 2026.
BNP Paribas Financial Markets bought 523,730 Takeda Pharmaceutical shares in Q2 2026, an estimated $8.67M.
Takeda Pharmaceutical made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1559 holding.
BNP Paribas Financial Markets first reported a position in Takeda Pharmaceutical in Q2 2019 and has held it in 29 quarters since.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.